Mitochondria are dynamic intracellular organelles that play a central role in oxidative metabolism and apoptosis. The recent resurgence of interest in the study of mitochondria has been fuelled in large part by the recognition that genetic and/or metabolic alterations in this organelle are causative or contributing factors in a variety of human diseases including cancer. Several distinct differences between the mitochondria of normal cells and cancer cells have already been observed at the genetic, molecular and biochemical levels. As reviewed in this article, certain of these alterations in mitochondrial structure and function might prove clinically useful either as markers for the early detection of cancer or as unique molecular sites against which novel and selective chemotherapeutic agents might be targeted.
Early studies of differences between the mitochondria of normal cells and those of cancer cells focused on the respiratory deficiencies common to rapidly growing cancer cells. This led Otto Warburg to propose in 1930 that respiratory deficiency might result in dedifferentiation of cells and hence neoplastic transformation (Refs 1, 2). Other early studies suggested that transformation was the result of submolecular micro-electronic changes involving errant dismantling and rebuilding of the electron transport chain during cell division (Ref. 3) , and that mutations in mitochondria might cause cancers (Ref. 4) . More recently, a great deal of research has been conducted that substantiates, extends and provides new insight into the role of mitochondria in cancer ( Refs 5, 6, 7, 8) . This review summarises the important aspects of mitochondrial structure and function, highlights the observed differences in mitochondria between normal and cancer cells, and discusses how these differences might be exploited in the detection and treatment of cancer.
Mitochondria structure, function and genome

Historical perspective
Early cytological studies (reviewed in Ref. 9) indicated the presence of subcellular granules similar in size and shape to bacteria in a variety of different cell types. In 1890, Altman postulated that these granules, which he termed 'bioblasts', expert reviews in molecular medicine
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were the basic units of cellular activity. Interestingly, Altman further speculated that bioblasts were capable of an independent existence, yet formed a colonial association with the cytoplasm of a host cell, and that it was through this association that the host cell acquired the properties of life. The term 'mitochondrion', meaning thread-like granule, was first applied to these subcellular structures by Benda in 1898 .
During the period 1900-1930, most cytologists recognised the mitochondrion as a well-defined and ubiquitous organelle, although at that time there was no agreement about its function. The identification of mitochondria as centres of energy metabolism came at the heels of refinements in cell fractionation techniques during the late 1940s, which allowed the successful separation of relatively pure, functionally intact mitochondria from other cellular components in liver cell homogenates (Refs 10, 11) . By 1949, these mitochondrial fractions were shown to contain succinate oxidase and cytochrome oxidase activities, as well as the enzyme systems required for fatty acid oxidation and the citric acid cycle (Refs 12, 13; reviewed in Ref. 9 ). Today, it is known that mitochondria produce up to 80% of the energy needs of a cell and perform a host of additional cellular functions.
Mitochondrial structure
The mitochondria of different tissues are similar in their gross morphology (reviewed in Ref. 9 ). In electron micrographs of fixed tissue specimens, mitochondria are most commonly observed as oval particles, 1-2 µm in length and 0.5-1 µm in width. These dimensions approximate to those of the bacterium Escherichia coli. The organelle is bounded by two membranes. The peripheral, or outer, membrane encloses the entire contents of the mitochondrion. The inner membrane has a much greater surface area and forms a series of folds or invaginations, called cristae, which project inward towards the interior space of the organelle. The total surface area of the inner membrane varies considerably depending upon the tissue and type of cell. Since the enzymes involved in oxidative phosphorylation are located on the inner mitochondrial membrane, its surface area and number of cristae are generally correlated with the degree of metabolic activity exhibited by a cell. The spatial arrangement of the outer and inner membranes creates two distinct internal compartments: the intermembrane space is located between the outer and inner membranes; and the matrix is the space enclosed by the inner mitochondrial membrane.
By contrast to the static, 'cigar-shaped' organelles commonly observed in electron micrographs, living cells stained with the lipophilic cation rhodamine 123 (Rh123) and observed by fluorescence microscopy reveal mitochondria as a dynamic network of long filamentous structures, capable of profound changes in size, form and location (Ref. 14) . These mitochondria can be seen extending, contracting, fragmenting and even fusing with one another as they move in three dimensions throughout the cytoplasm. Interestingly, the treatment of cells with microtubule-depolymerising agents has been shown to result in an altered distribution of mitochondria (Refs 15, 16) . This suggests that mitochondria are associated with and travel along a molecular 'highway' composed of a cytoplasmic microtubule network.
Mitochondrial function
Mitochondria play a central role in oxidative metabolism in eukaryotes (reviewed in Ref. 9 ). In the catabolism of carbohydrates (Fig. 1a) , this begins with the transport of pyruvate from the cytosol into the mitochondrion, and its subsequent oxidative decarboxylation to acetyl CoA by a soluble, multi-enzyme pyruvate dehydrogenase complex, which is located in the mitochondrial matrix. The oxidation of acetyl CoA is achieved by a cyclic process involving eight catalytic steps. This process is known as either the citric acid or the tricarboxylic acid (TCA) cycle. All but one of the TCA cycle enzymes are soluble proteins found in the inner mitochondrial matrix compartment. The single insoluble enzyme, succinate dehydrogenase, is tightly bound to the matrix side of the inner mitochondrial membrane. Each round of the TCA cycle results in the production of two molecules of CO 2 , three molecules of reduced nicotinamide adenine dinucleotide (NADH), one molecule of reduced flavin adenine dinucleotide (FADH 2 ), and one molecule of GTP (the energetic equivalent of ATP).
The next stage of aerobic metabolism is oxidative phosphorylation, an energy-generating process that couples the oxidation of respiratory substrates (such as the NADH and FADH 2 generated through the TCA cycle) to the synthesis of ATP. Substrate oxidation involves a series of expert reviews in molecular medicine Mitochondria as targets for detection and treatment of cancer Figure 1 . Schematic of key mitochondrial metabolic pathways. (a) Carbohydrate metabolism. Pyruvate produced from glycolysis undergoes oxidative decarboxylation to acetyl CoA, which is then oxidised in an eight-step process known as the tricarboxylic acid (TCA) cycle. The respiratory substrates NADH and FADH 2 generated through the TCA cycle are next oxidised in a process coupled to ATP synthesis. Electrons are transferred from NADH and FADH 2 to oxygen via enzyme complexes located on the inner mitochondrial membrane. Three of the electron carriers (complexes I, III and IV) are proton pumps, and couple the energy released by electron transfer to the translocation of protons from the matrix side to the external side of the inner mitochondrial membrane. Energy stored in the resulting proton gradient (i.e. the proton-motive force) is used to drive the synthesis of ATP via the mitochondrial enzyme ATP synthetase (complex V). (b) Fatty acid oxidation. Fatty acids undergo oxidative decarboxylation in the mitochondrial matrix to give acetyl CoA, which is fed into the TCA cycle, and new acyl CoA molecules that are successively shortened with each round of the cycle. Under certain conditions (e.g. fasting), acetyl CoA molecules are converted into ketones for use as an alternative energy source. (c) Urea cycle. Amino acid degradation resulting in excretion of nitrogen as urea occurs partly in the mitochondrion. The mitochondrion is also essential for several other processes (not shown), including gluconeogenesis, regulation of cytosolic NAD + , intracellular homeostasis of inorganic ions, and apoptosis (fig001ksb). The energy released by the exergonic transfer of electrons from respiratory substrate to oxygen is coupled to the translocation of protons from the matrix side to the external side of the inner mitochondrial membrane at three sites: respiratory enzyme complexes I, III and IV. In intact, well-coupled mitochondria, the inner membrane is relatively impermeable to the back flow of these protons. According to the Chemiosmotic Hypothesis, which was first proposed by Peter Mitchell in 1961 (and for which he received the Nobel Prize in Chemistry in 1978), the energy stored in the resulting proton gradient (i.e. the proton-motive force) is used to drive the synthesis of ATP via complex V, the mitochondrial enzyme ATP synthetase (Ref. 17) .
The ATP that is produced by aerobic metabolism and not used by the mitochondrion is transported across the inner mitochondrial membrane in exchange for cytosolic ADP by the enzyme adenine nucleotide translocase (ANT). This exchange ensures not only the availabilty of mitochondrial ADP, which is the principal control molecule for the rate of oxidative phosphorylation, but also the availability of cytosolic ATP. Oxidative phosphorylation thus supplies a majority of the cellular energy produced under aerobic conditions and required to sustain cell viability and normal cell functions.
Fatty acid oxidation is another important metabolic activity located in the mitochondria (Fig. 1b) . The beta-oxidation pathway involves four separate enzymes that are soluble in the mitochondrial matrix and that function in a repetitive cycle. With each round of the cycle, a fatty acid undergoes oxidative decarboxylation to produce one molecule of acetyl CoA and one molecule of a new acyl CoA that is two carbons shorter than the starting fatty acid. The process continues until the original fatty acid molecule is completely degraded to acetyl CoA (for example, the 16-carbon palmitoyl CoA would undergo seven rounds of beta-oxidation to yield eight molecules of acetyl CoA). The acetyl CoA molecules thus generated normally enter into the TCA cycle where they undergo oxidation to CO 2 . However, during conditions of prolonged fasting and starvation, or in certain metabolic diseases (e.g. diabetes mellitus), the acetyl CoA molecules generated by fatty acid oxidation are converted into ketones (e.g. β-hydroxybutyrate, acetoacetate and acetone) by enzymes also located in the mitochondrial matrix. These molecules are then transported through the blood to other tissues, such as brain and heart, where they are used as an alternative energy source to glucose.
In addition to its central role in oxidative metabolism, the mitochondrion is involved in a variety of other important cellular functions. For example, certain enzymes of the urea cycle ( Fig.  1c ) and gluconeogenesis are located in the mitochondrial matrix. Mitochondria are involved in the regeneration of cytosolic NAD + (required for the substrate-level phosphorylation step in glycolysis) and in the intracellular homeostasis of inorganic ions such as calcium and phosphate. A wealth of recent studies show that mitochondria also play an integral role in the cascade of intracellular events that lead to apoptosis, or programmed cell death (Refs 18, 19).
Mitochondrial genome
Mammalian cells typically contain 10 
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one of four respiratory enzyme complexes localised to the inner mitochondrial membrane. They include seven subunits of respiratory enzyme complex I, one subunit of complex III, three subunits of complex IV, and two subunits of complex V. All other mitochondrial proteins, including those involved in the replication, transcription and translation of mtDNA, are encoded by nuclear genes and are targeted to the mitochondrion by a specific transport system (Ref. 20) . In humans and other mammals, mitochondrial genes display a maternal inheritance (i.e. are inherited from the female parent). This is probably because the number of mtDNA copies in the egg is typically 10 3 -fold greater than that in the sperm (Ref. 21) . Alternatively, paternal genomes and organelles might be preferentially degraded in the zygote (Refs 22, 23) .
Although the mitochondrial and nuclear genomes are physically distinct, the high degree of functional interdependence between them is suggestive of a host-parasite relationship. The 'endosymbiont' theory proposes that early in the evolution of the eukaryote, a primitive protoeukaryote cell that was incapable of aerobic respiration served as host to a eubacterium with the unique capacity for oxidative metabolism (Ref. 24) . During the early stages of this endosymbiotic association, the eubacterium retained its genetic autonomy. In time, however, most of its genetic material was transferred to the nuclear genome of the host. The resulting mitochondrion retained only those few (i.e. 13) genes encoding polypeptides that are essential to aerobic ATP production yet have a hydrophobicity that precludes nuclear synthesis and cytoplasmic transport to mitochondria. It is of interest to recall Altman's perceptive characterisation of mitochondrial function, and his suggestion of a colonial association between the newly discovered 'bioblasts' and the host cell within which they reside.
Mitochondria and disease
The first mitochondrial disease was described by Rolf Luft in 1962 (Ref. 25 ), a year prior to the discovery of mtDNA (Ref. 26) . At the genetic level, mitochondrial disease was not definitively described until 1988 with the identification of mtDNA mutations in patients with mitochondrial myopathies, as well as the molecular genetic characterisation of patients with Leber's hereditary optic neuropathy and familial mitochondrial encephalomyopathy (Refs 27, 28, 29). Since then, there has been a steady growth in the list of diseases associated with mitochondrial dysfunction arising from mtDNA mutations (Table 1) .
Although mtDNA represents less than 1% of total cellular DNA, its gene products are essential for normal cell function. Unlike nuclear DNA, mammalian mtDNA contains no introns, has no protective histones and is exposed to deleterious Alterations in the molecular composition of the inner membranes of tumour mitochondria have also been noted ( Refs 53, 54, 55, 56, 57, 58) . Polypeptide profiles of normal liver versus hepatoma mitochondria demonstrate differences in the appearance and/or relative abundance of several protein subunits. One major band that is deficient or absent in several tumours studied has a mobility near or equal to the B subunit of the F 1 -expert reviews in molecular medicine
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ATPase (approximately 57 kDa). Other bands that are present in tumour mitochondria appear to be deficient or absent in control mitochondria. In addition, analysis of the inner membrane lipid composition of various tumour mitochondria has indicated elevated levels of cholesterol, varying total phospholipid content, and/or changes in the amount of individual phospholipids relative to normal controls.
Many differences in the mitochondria of normal versus transformed cells have also been noted with regard to: (1) the preference for substrates oxidised; (2) the magnitude of the acceptor control ratio; (3) the rates of electron and anion transport; (4) the capacity to accumulate and retain calcium; (5) the amounts and forms of DNA; and (6) the rates of protein synthesis and organelle turnover. However, there is apparently no universal metabolic alteration that is common to all tumours. For example, although the pathogenesis of prostate cancer involves the mitochondrial metabolic transformation of citrateproducing cells to citrate-oxidising cells, this metabolic abnormality is not reported in other cancers (Ref. 59) . Additionally, it is important to note that the altered metabolism in cancer cells is probably not the cause of malignancy but, rather, a secondary, albeit essential, adaptation to support malignant activities (Ref. 59 ).
Rh123 uptake
In the early 1980s, Chen and colleagues discovered an interesting phenotype that was found to be common to nearly all types of carcinoma tested (Refs 14, 60, 61). It was observed that the lipophilic cation Rh123 could serve as a highly specific vital stain for mitochondria, providing lowbackground, high-resolution fluorescent images of the organelle in a variety of cell types (Fig. 2) . It was further observed that relative to the mitochondria of normal epithelial cells, the mitochondria of carcinoma cells displayed an increased uptake and prolonged retention of Rh123, and that this phenomenon correlated with a selective cytotoxicity for carcinoma cells in vitro and in vivo (Refs 62, 63, 64). For example, whereas Rh123 was shown to have a minimal effect on the clonal growth of those cell types that display little uptake and short retention of the dye (e.g. primary cultures of normal mouse bladder epithelial cells; and CCL-34 and BSC-1, the non-tumourigenic dog and monkey kidney epithelial cell lines, respectively), it markedly inhibited the clonal growth of those cultured carcinomas cell lines that display high uptake and prolonged retention of Rh123 (e.g. MB49, the transformed mouse epithelial cell line; and MCF-7 and HUT, the human breast and lung carcinoma cell lines, respectively). In addition, at a constant exposure of 10 µg/ml Rh123, greater than 50% cell death occurred within seven days in 9/9 of the carcinoma cell types tested, whereas 6/6 control epithelial cell types remained unaffected. Standard chemotherapeutic agents such as arabinosyl cytosine (Ara-c) and methotrexate exhibit no such selectivity for carcinoma cells. In vivo, Rh123 was shown to prolong the survival of mice implanted with Ehrlich ascites tumour or MB49 mouse bladder carcinoma cells as much as 260%, although the extent of survival prolongation was highly dependent on the dose and schedule of administration of the dye. As expected, Rh123 did not significantly prolong the survival rate of mice implanted with tumours of cell types shown to be short retainers of the dye (e.g. L1210 and P388 leukaemias, and B6 melanoma). 
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Increased membrane potential in carcinoma cells
It became apparent from early studies that two chemical properties of Rh123 were important in promoting its uptake into mitochondria. The first is the lipophilicity of Rh123, which allows the compound to penetrate the hydrophobic barriers of the plasma and mitochondrial membranes; and the second is its electrical charge -rhodamines that are positively charged at physiological pH stain mitochondria specifically, whereas the neutral rhodamines do not (Ref. 14 
Delocalised lipophilic cations
Rh123 provided a prototype for a new class of anti-cancer agents that exploit the difference in mitochondrial membrane potential between normal epithelial and carcinoma cells to achieve a selective mitochondrial toxicity and consequent selective cytotoxicity for carcinoma cells. In the past few years, several members of this class of compounds, known collectively as delocalised lipophilic cations (DLCs), have exhibited at least some degree of efficacy in carcinoma cell killing in vitro and/or in vivo ( Refs 70, 71, 72, 73, 74, 75) . For example, dequalinium chloride (DECA) has demonstrated 100-fold greater inhibition of the clonal growth of carcinoma versus control epithelial cells in culture, anti-carcinoma activity in human colon adenocarcinoma cells injected subcutaneously in nude mice, and significant regression of tumours in rats carrying in situ mammary adenocarcinomas induced by dimethyl-bezanthracene (Refs 71, 72). The thiopyrylium AA-1 was shown to prolong the survival of mice implanted with either mouse bladder carcinoma, human melanoma, and human ovarian carcinoma cell lines, achieving treated:control ratios as high as 450% (Ref. 74 ). The rhodacyanine MKT-077 also appears particularly promising (Refs 73, 76, 77) . In recent studies, MKT-077 demonstrated significant growth-inhibitory activity against a variety of keratin-positive human cancer cell lines, as measured by clonogenic assays and growth inhibition of cultured cells. In vivo, MKT-077 demonstrated significant anti-tumour activity in nude mice implanted with either the human melanoma LOX, the human renal carcinoma A498, or the human prostate carcinoma DU145, all of which are highly refractory to a variety of traditional therapies. As the first DLC with a favourable pharmacological and toxicological profile in preclinical studies, MKT-077 has undergone Phase I clinical trials, approved by the US Food and Drug Administration, for the treatment of carcinoma.
Mechanism of action of DLCs
It is of interest to note that, although all DLCs are taken up into mitochondria by a common expert reviews in molecular medicine Mitochondria as targets for detection and treatment of cancer mechanism (i.e. in response to negative-inside transmembrane potentials), the mechanism of mitochondrial toxicity exhibited by these compounds is quite varied. For example, among the DLCs that display a concentration-dependent toxicity to mitochondria, Rh123 and AA-1 inhibit mitochondrial ATP synthesis at the level of F 0 F 1 -ATPase activity (Refs 68, 74), whereas DECA and certain DLC thiacarbocyanines interfere with NADH-ubiquinone reductase activity (Refs 70, 72) . In addition, the selective cytotoxicity to carcinoma cells exhibited by MKT-077 in vitro and in vivo has been attributed to a selective inhibition of mitochondrial respiration in cancer cells, most probably as a result of a general perturbation of mitochondrial membranes and consequent inhibition of the activity of membrane-bound enzymes (Ref. 76) . The selective cytotoxicity might also be a consequence of a mild to moderate degradative effect on mtDNA, but not nuclear DNA, of various carcinoma cell types (Ref. 76) .
It is of further interest to note that, although increased membrane potential is necessary to achieve selective cytotoxicity by DLCs, it alone is not sufficient. If this were the case then cardiac muscle cells, which have also been shown to exhibit a high mitochondrial membrane potential (Ref. 78) , would be susceptible to the cytotoxic effects of these compounds. Yet significant cardiac toxicity has not been observed following in vivo administration of either MKT-077 or DECA. This suggests the sensitivity of any particular cell type to the effects of DLCs might depend on different cytoplasmic characteristics, such as those involving the kinetics of uptake and retention of the compound, or on properties inherent to the mitochondria, such as differential sensitivity of the target molecule against which the DLC exerts its cytotoxic effect.
DLCs and photochemotherapy
Some research groups have explored the use of certain DLCs in photochemotherapy (PCT), an investigational cancer treatment involving light activation of a photoreactive drug, or photosensitiser, that is selectively taken up or retained by malignant cells (Refs 79, 80, 81, 82 ). There has been considerable interest recently in PCT as a form of treatment for neoplasms of the skin, lung, breast, bladder, brain or any other tissue accessible to light transmitted either through the body surface or internally via fibre optic endoscopes. Cationic photosensitisers are particularly promising as potential PCT agents. Like other DLCs, these compounds are concentrated by cells into mitochondria in response to negative-inside transmembrane potentials, and are thus selectively accumulated in the mitochondria of carcinoma cells. In response to localised photoirradiation, the photosensitiser can be converted to a more reactive and highly toxic species, thus enhancing the selective toxicity to carcinoma cells and providing a means of highly specific tumour cell killing without injury to normal cells.
Several cationic photosensitisers have shown promise for use in PCT. For example, selective phototoxicity of carcinomas in vitro and in vivo has been observed for a series of triarylmethane derivatives (Ref. 83) , and for 2-ethyl-1,3-dioxylene kryptocyanine (EDKC) (Ref. 77) . Both Rh123 and the chalcogenapyrylium dye 8b have been evaluated as photosensitisers for the photochemotherapy of malignant gliomas (Refs 84, 85, 86). As is the case for the nonphotosensitising DLCs, the mitochondrion has been implicated as an important, perhaps primary, subcellular site of damage by these and several other cationic photosensitisers (Refs 79, 87, 88, 89, 90, 91). Again, the mechanisms of mitochondrial toxicity exhibited by these compounds have been shown to vary from an inhibition of NADHubiquinone reductase (e.g. in the case of EDKC, and the triarylmethane derivative VB-BO) to a non-specific perturbation of mitochondrial function most probably resulting from membrane damage induced by singlet oxygen (e.g. in the case of certain chalcogenapyrylium dyes). More recently, photoactivation has been shown to enhance the mitochondrial toxicity of MKT-077, with evidence for the involvement of lipid peroxidation in this process. These results have positive implications for the use of MKT-077 in PCT.
Future directions for research involving DLCs
Although the use of DLCs as anti-cancer agents has shown promise, as yet there is no real understanding of the biochemical basis for the increased mitochondrial membrane potential in carcinoma cells. Consequently, the choice for the design or selection of potentially therapeutic lipophilic cations has been based almost solely on physical properties (i.e. lipid solubilty, expert reviews in molecular medicine Mitochondria as targets for detection and treatment of cancer delocalisation of positive charge, etc.), and preliminary screening for the selective cytotoxicity of these compounds has been empirical. Although there is sufficient evidence to support the idea that a therapeutic mechanism based on differences in mitochondrial membrane potential might be exploited for the treatment of cancers, a knowledge of the specific biochemical alterations that account for increased mitochondrial membrane potential in these cells would undoubtedly lead to a more rational approach to the choice of highly selective DLCs for clinical use. To this end, a comprehensive, comparative biochemical analysis of mitochondria isolated from several control and carcinoma cell lines that display differences in mitochondrial membrane potential is currently under way (J.S. ModicaNapolitano, unpublished). This type of study will contribute to an understanding of the phenomenon of increased uptake of DLCs by carcinoma mitochondria and might also reveal molecular differences between the mitochondria of normal epithelial and carcinoma cells against which novel, selective and site-specific DLCs could be targeted. The information obtained will be used in the rational design of a more efficacious form of DLC that exhibits a dual selectivity for carcinoma cells based on both differential accumulation and selective action against a unique molecular target.
Molecular basis for increased membrane potential in carcinoma cells
It is logical to assume that the observed differences in the magnitude of the mitochondrial membrane potential between normal epithelial and carcinoma cells might arise from differences in the structure and function of one or more of those organelle components that serve to create and/or maintain the electrical gradient. Possibilities include differences in mitochondrial respiratory enzyme complexes, electron carriers, ATP synthetase, ANT and membrane lipid structure. Differences that affect electron transfer activity, or proton translocation, utilisation or conductance, are also candidates for the molecular basis for increased mitochondrial membrane potential in carcinoma cells.
Interestingly, some differences of these types are already known to exist between the mitochondria of normal and malignant cells. For example, under certain assay conditions, mitochondria isolated from hepatomas of varying growth rates and degrees of differentiation display a decreased capacity for uncouplerstimulated ATP hydrolysis relative to that found in normal liver (Ref. 92) . In addition, mitochondria isolated from biopsies of human hepatocellular carcinoma have decreased rates of respiration-linked ATP synthesis and a reduced phosphorylative capacity compared with normal human liver (Refs 93, 94) . Furthermore, the measured maximal velocity for ATPase activity in submitochondrial particles isolated from hepatocellular carcinoma is considerably lower than that in normal liver. It has been suggested that these alterations in enzyme function might be associated with a decrease in immunodetectable levels of the B subunit of the It is not clear whether the decrease in specific activity of COX in cancer cells can be explained by alterations in the level of gene expression. For example, in one study involving human colonic biopsies, the mean level of expression of mitochondrially encoded COX subunit III was found to be lower in carcinoma versus normal mucosa samples (Ref. 99) . Cultured HT29 colon carcinoma cells also exhibited low levels of the COX III transcript; however, expression of COX III returned to higher (normal) levels when the cells were induced to differentiate by exposure to sodium butyrate. By contrast, increased expert reviews in molecular medicine Mitochondria as targets for detection and treatment of cancer levels of RNA transcripts of the nuclear-encoded subunit COX IV and mitochondrially encoded COX subunits I and II have been observed in Zajdela hepatoma as compared with normal liver (Ref. 100) .
Alternatively, and perhaps more interestingly, the decreased specific activity of COX in tumour mitochondria might reflect a kinetic difference caused by genetic mutations that alter the structure and function of the enzyme. These same structural changes might be hypothesised to affect the proton-pumping capacity of the enzyme, and thus the magnitude of the mitochondrial membrane potential.
Mitochondrial permeability transition pore activity
The magnitude of the mitochondrial membrane potential might also be dependent upon membrane permeability as regulated generally by the membrane lipid-protein structure, or more specifically by the mitochondrial permeability transition pore (MPTP). This is a multi-protein structure formed at contact sites between the inner and outer mitochondrial membranes. It is a voltage-dependent, cyclosporin-A-sensitive, high-conductance inner membrane channel, the opening of which transiently depolarises the mitochondrial membrane potential. Although the complete physiological role of the MPTP is unknown at this time, it is probably involved in the early apoptotic changes that affect mitochondrial membrane permeability. Several differences have been found when comparing the MPTP in normal versus malignant cells.
One of the key structural components of the MPTP complex is ANT. The primary role of ANT is to facilitate the one-for-one exchange of ATP (out) for ADP (in) across the inner mitochondrial membrane. More recently, it has been suggested that ANT also acts as a non-specific pore that renders the mitochondrial inner membrane permeable to solutes less than 1.5 kDa in size (Ref. 101) . Interestingly, the adenine nucleotide exchange function of ANT is known to be decreased in certain hepatoma versus normal liver mitochondria (Refs 102, 103, 104 ). In addition, the sensitivity of this enzyme to bongkrekic acid, an inhibitor of both adenine nucleotide exchange and formation of the MPTP is also decreased in hepatoma versus normal liver (Refs 104, 105, 106) . Furthermore, high transcript levels for ANT2, the gene encoding one of three isoforms of the translocase, have been observed in several dedifferentiated, proliferating, renal tumour cell types, whereas expression of ANT2 is usually repressed in quiescent cells (Refs 107, 108) .
Additional known or putative MPTP components also exhibit alterations in gene expression between normal and cancer cells. Among those genes overexpressed in cancer cells are the anti-apoptotic oncogenes encoding Bcl-2 and Bcl-XL, which have a direct inhibitory effect on pore opening, and genes encoding the peripheral benzodiazepin receptor (PBR), the PBR-associated protein Prax-1, and mitochondrial creatine kinase (Refs 109, 110, 111, 112, 113, 114,  115, 116) . Conversely, the expression of BAX, a proapoptotic, inner mitochondrial membrane protein that facilitates pore opening, has been shown to be reduced in some cancer cell lines (Refs 117, 118). However, whether these changes in gene expression contribute to steady-state differences in membrane permeability between normal epithelial and carcinoma cells has yet to be determined.
Mitochondrial DNA mutations in carcinoma cells
Mitochondrial dysfunction is one of the most profound features of cancer cells. Consistently, mutations in mtDNA have been reported in a variety of cancers. These include ovarian, thyroid, salivary, kidney, liver, lung, colon, gastric, brain, bladder, head and neck, and breast cancers, and leukaemia (see Table 2 for references). The types of mutations observed in mtDNA range from point mutations, to deletions and duplications. Most tumours contain homoplasmic (100% pure) mutant mtDNA because of the clonal nature of cancers (Refs 5, 6, 119).
The abundance and homoplasmic nature of mitochondria make mtDNA an attractive molecular marker of cancer. Indeed, mutant mtDNA in tumour cells is reported to be 220 times as abundant as a mutated nuclear marker (Ref. 119) . Furthermore, a recent study of mtDNA from patients with bladder, head and neck, and lung cancers reported that mutated mtDNA is readily detectable in urine, blood and saliva samples from these patients (Ref. 119). Thus, mtDNA mutation might prove to be an extremely useful biomarker for the detection of many cancers. Ongoing research on DNA repair genes involved in maintaining the genetic integrity of the mitochondrial genome combined with further expert reviews in molecular medicine
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analysis of the nature of mtDNA mutations will greatly aid progress in this area.
Mitochondrial dysfunction also has important implications in cancer therapy. This has been demonstrated by measuring the cell survival of a cervical tumour cell line (with parental mitochondrial function, i.e. Rho + ) and its derivative isogenic cell line that completely lacked mtDNA (with dysfunctional mitochondria, i.e. Rho 0 ) after exposure to a variety of anti-cancer agents (Ref. 119) . It was found that mitochondrial dysfunction leads to increased cell survival after exposure to cancer therapeutic agents such as adriamycin and porphyrin-catalysed phototoxicity. By contrast, no measurable difference was found in the cell survival of the Rho + and Rho 0 cells to high doses of ionising radiation. These results underscore the importance of the mitochondrial genome in development of cancer therapeutic drugs.
Concluding remarks and clinical implications
The many distinct differences in mitochondrial structure and function between normal cells and cancer cells offer a unique potential for the clinical use of mitochondria as markers for the early detection of cancer. Additionally, these differences offer the possibility for the design and synthesis of effective anti-cancer agents that deliver potent mitochondrial inhibitors to selectively kill tumour cells (reviewed in Ref. 120 Traditional chemotherapies, aimed at DNA replication in actively dividing cells, have achieved only limited success in the treatment of cancer largely because of their lack of specificity for cells of tumourigenic origin. It is important, therefore, to search for novel cellular targets that are sufficiently different between normal cells and cancer cells so as to provide a basis for selective cytotoxicity. As this review suggests, the mitochondrion is one such target. Tables   Table 1. Mitochondrial diseases (tab001ksb). Table 2 . Mitochondrial DNA mutation in cancers (tab002ksb).
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